Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).

A. Okines,Elisavet Paplomata,Tanya A. Wahl,G. Wright,Stephanie Sutherland,Erik Jakobsen,Frances Valdes,Arlene Chan,Amy S. Clark,Alison Katherine Conlin,Maryam B. Lustberg,Jennifer M. Specht,Timothy J. Pluard,Xiaofu Zhu,Ian E. Krop,Karen A. Gelmon,Dennis J. Slamon,Jorge Ramos,Grace An,Erika Paige Hamilton

Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).

2020

1043Background: Tucatinib (TUC) is an investigational TKI, highly selective for HER2 without significant inhibition of EGFR. HER2CLIMB is a randomized trial of TUC vs placebo in combination with tr...

Keywords:

Oncology
Metastatic breast cancer
Trastuzumab
in patient
Internal medicine
Capecitabine
Pathology
Adverse effect
Medicine
highly selective
Placebo
Randomized controlled trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations